Activated guidewire crosses chronic occlusions
This article was originally published in Clinica
An activated guidewire technique looks promising in improving the success rate of coronary angioplasty for chronic occlusions, suggests a UK study (The Lancet, October 7th). The hand-held, battery-driven motorised device, developed by Prof Michael Rees at the University of Keele (see Clinica No 622, p 18), is attached to standard angioplasty equipment. Complex vibratory movements produced in the guidewire increase the force with which the wire impacts the lesion, and the effective surface area over which the wire probes the lesion.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.